Canadian Eye Care Professionals and their Patients to Benefit from Innovative New Services, Increased Support, and Best-in-Class Products

Oakville, ON: May 10th 2022 – As two world-class family companies with a passion for eye care, Laboratoires Théa and Labtician Ophthalmics recognized an opportunity to work together to bring innovative new products to Canadian patients. In 2018, this shared vision resulted in the formation of Labtician Théa, an ambitious Joint Venture with a 5-year term.

By focusing on supporting Canadian Eye Care professionals provide optimal care to their patients, the Labtician Théa Joint Venture has achieved its goals of creating a strong presence in the Canadian marketplace and offering Canadian Eye Care Professionals the most comprehensive suite of products and services available in the industry. From diagnostics and surgical equipment that provide solutions across Cornea, Glaucoma and Retinal Diseases, to cutting-edge preservative-free treatments for the management of Glaucoma, Dry Eye Disease and Lid Hygiene, Labtician Théa has brought innovation to practice for clinicians and their patients.

With the successful completion of the agreed-upon 5-year term, as of January 1, 2023, the Joint Venture will terminate, resulting in a stronger Labtician Ophthalmics with a new Therapeutics Division to complement its existing Surgical Division, and the launch of Théa Pharma Canada Inc., an affiliate of Laboratoires Théa, based in the Greater Toronto Area. As two separate entities, Labtician Ophthalmics and Théa Pharma Canada will be better positioned to service and support the Canadian Eye Care community for many years to come.

“Our partnership with Labtician Ophthalmics has allowed us to get to know the Canadian Eye Care professionals and understand their needs and that of their patients. It was a great way to introduce them to Théa and bring innovative best-in-class products to market that are supported by strong clinical evidence,” says Fiona McCloskey, Managing Director of Labtician Théa and Théa Pharma Canada. “Since the start of the Joint Venture with Labtician Ophthalmics, Eye Care Professionals and patients have come to know and trust Théa products, allowing us to build a reputation and truly make a difference in patient lives every day. With the launch of Théa Pharma Canada in 2023, our goal is to continue to provide ECPs and patients with new innovative treatments and solutions for a wide range of ocular diseases including Dry Eye, Glaucoma, Allergy and more over the years to come. We are thankful for our partnership with Labtician Ophthalmics and excited for this new chapter in our journey as Théa Pharma Canada.”

This unique Joint Venture has also been a success for the team at Labtician Ophthalmics.

“Working with the world-class team and products at Théa allowed us to demonstrate our unique ability to platform other companies in the Canadian marketplace and showcase our skill of developing unprecedented business models and executing against them,” says Polydor Strouthos, President of Labtician Ophthalmics. “We built on our expertise in regulatory, cross-functional marketing, and customer expansion, and increased our capacity to launch products and entities. We bring innovation to practice and will provide our valued customers with more best-in-class products, services, and innovative solutions due to a stronger Labtician Ophthalmics with a new Therapeutics Division to complement our existing Surgical Division.
When mutually beneficial opportunities arise, Théa Pharma Canada Inc. and Labtician Ophthalmics Inc. will leverage their strong relationship and shared family values as Partners of Choice, and look forward to robust, sustained growth for both companies in the years to come.

For More Information:
Fiona McCloskey, Managing Director
Labtician Théa and Théa Pharma Canada
Tel: 416-669-0585
Fiona.McCloskey@labticianthea.com

Polydor Strouthos, President
Labtician Ophthalmics, Inc.
Tel: 905-829-0055 ext. 227
pstrouthos@labtician.com

ABOUT LABTICIAN OPHTHALMICS, INC.

Labtician Ophthalmics, Inc. is a solutions-focused provider of specialty medical devices and pharmaceutical products to the Canadian Eyecare community. With 60 years of history in Canada, Labtician Ophthalmics Inc. continues its tradition of bringing innovation to practice through the commercialization of exclusive and innovative medical devices for use in surgery. Now as a stronger Labtician Ophthalmics with a new Therapeutics Division to complement the existing Surgical Division we provide our valued customers with even more best-in-class products, services, and innovative solutions including our expertise in launching products and entities into the Canadian marketplace.

ABOUT THÉA PHARMA CANADA INC.

Théa Pharma Canada, Inc. is an affiliate of Théa, the leading independent Eye Care group in Europe specializing in the research, development, and commercialization of products exclusive to Eye Care. With over 150 years of history, the family owned and run company is the pioneer and leader in the development of preservative-free treatments. Today, it constitutes a network of more than 1500 employees worldwide, and its products are available in more than 75 countries. With the launch of Théa Pharma Canada in 2023, our goal is to continue to provide ECPs and patients with innovative treatments and cutting-edge solutions for a wide range of ocular diseases including Dry Eye, Glaucoma, Allergy and more over the years to come.

     

CAN Health Network and Quebec-Based DIAGNOS Announce Life-Changing Diabetic Retinopathy Screening Program Partnership

Innovative diabetic retina screening service resulting in earlier intervention, better care, and savings to the Canadian healthcare system.

March 15, 2022 (Montréal, Québec) – The Coordinated Accessible National (CAN) Health Network is excited to announce that leading vision care company, DIAGNOS, is the first Quebec-based organization to join the Network. Through their strategic partner, Labtician Ophthalmics Inc, a Toronto-based company with Eyecare Specialist customers across Canada, DIAGNOS’ CARA solution will help health care professionals in their day-to-day screening of diabetic patients by allowing them to monitor ocular health, ultimately helping to prevent vision loss in their patients.

Diabetic Retinopathy is the leading cause of blindness, and early detection has been identified as the best preventative measure and solution. Patients who require these critical screenings often come up against barriers resulting in non-compliance, high costs, or a missed diagnosis, leading to potentially life-altering vision loss. In particular, DIAGNOS’ solution will help professionals identify patients who are overdue for a screening, ensuring Diabetic Retinopathy is caught early. This low-cost, non-invasive state-of-the-art technology involves the use of a simple rear eye camera image, which quickly and effectively screens patients. Assessment results are then returned within a few minutes; saving both time and health care costs.

“DIAGNOS, a publicly traded company on the TSX Venture Exchange, is pleased to be part of the CAN-Health Network,” said André Larente, CEO, DIAGNOS. “Our solution for screening diabetic patients uses Artificial Intelligence. The CARA application is approved by Health Canada and is in use today in hospitals and primary care clinics. This new local screening program will give accessibility to all patients in Canada to a fast and low priced medical test.”

Funded by Government of Canada, the CAN Health Network works with health care providers to identify their biggest challenges, and matches them with Canadian-made technology solutions. This Integrated Market model allows Canadian innovators to gain access to the healthcare market, and rapidly validate and scale their solution across the country, and internationally.

“The CAN Health Network has been focused on accessing the Quebec marketplace to ensure a truly national scope and economic prosperity for all of Canada. Adding DIAGNOS and Labtician to the Network is another great step in ensuring all Canadians have access to the best home-grown innovative health care technologies,” said Dante Morra, Chair, CAN Health Network.

“We are pleased to be working with CAN Health Network and DIAGNOS, a Canadian company based in Quebec, in addressing growing needs in the monitoring of diabetic patients,” explains Labtician President, Polydor Strouthos. “For over 60 years, we’ve been introducing innovative eye care products, solutions, and resources for eyecare professionals and their patients in the Canadian marketplace. Through our extensive network, we commercialize our high-quality value add eyecare products as well as those of our forward-thinking partner companies in Canada and worldwide. We help companies through the complexities and nuances of Canadian and international markets, from prelaunch assistance and obtaining regulatory approval, to securing commercialization, and distribution channels.”

ASSOCIATED LINKS

• Government of Canada provides more support to CAN Health Network
• DIAGNOS
• Labtician Ophthalmics, Inc.

ABOUT DIAGNOS

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia). DIAGNOS works with AI Distributor, Labtician Ophthalmics (Labtician).

ABOUT CAN HEALTH

The CAN Health Network is a Canada-first approach to technology adoption. It helps break down barriers to scaling in the health care system and provides an environment for companies to scale to their full potential. Currently operating in Ontario, Western and Atlantic Canada, the CAN Health Network will soon be expanding into Quebec and the North. The Network has received a total of $12.45 million in funding from the Government of Canada to build a national platform that harnesses the purchasing power of health care organizations. To learn more about the CAN Health Network, visit canhealthnetwork.ca.

For more information:

Mr. Polydor Strouthos, President
Labtician Ophthalmics, Inc.
Tel: 905-829-0055 ext. 227
pstrouthos@labtician.com

Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca

Natasha Zelinski, Communications Coordinator
CAN Health Network
natasha.zelinski@thp.ca

DIAGNOS Announces its Exclusive Strategic Partnership Agreement with Labtician Ophthalmics, a Leader in Canadian and International Eyecare Markets to Address Growing Needs in the Monitoring of Diabetic and Hypertensive Patients

Brossard, Quebec, Canada – February 24, 2021 – Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF) a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces its exclusive strategic partnership agreement with Labtician Ophthalmics (“Labtician”), a Toronto-based company with customers across Canada who will introduce and commercialize DIAGNOS AI platform to monitor ocular health and improve patient care in diabetic patients. An initial agreement with Labtician was announced on June 3rd, 2020.

In an effort to increase its footprint and accelerate its growth, DIAGNOS has decided to work with organizations that are active in similar markets. The formalization of this strategic partnership with Labtician will have the net effect of allowing access to new customers across Canada. DIAGNOS’ CARA solution allows close monitoring of the effects of medications used in retinal microcirculation to help professionals in their day-to-day screening of their patients.

“We are pleased to be working with DIAGNOS in addressing growing needs in the monitoring of diabetic and hypertensive patients. For over 60 years, we’ve been world leaders in innovative eye care products, solutions, and resources for eyecare professionals and their patients. Through our extensive network, we commercialize our high-quality eyecare products as well as those of our forward-thinking partner companies in Canada and worldwide. We help companies through the complexities and nuances of Canadian and international markets, from prelaunch assistance and obtaining regulatory approval, to securing commercialization, and distribution channels,” explains Labtician President, Polydor Strouthos.

“I am pleased to be working with the team at Labtician. Labtician brings a high-level of expertise in the Canadian healthcare marketplace. Our growth strategy is to create partnerships in select countries thereby leveraging local relationships to accelerate the adoption of DIAGNOS’ CARA AI Platform. Labtician is the ideal partner due to their long history of working closely with Canadian Optometric and Ophthalmology professionals dedicated to treating the effects of diabetes on the eyes and preventing vision loss,” explains DIAGNOS CEO, André Larente.

Labtician worked with Prism Eye Institute, a CAN Health Network partner, to gain insights in how to best utilize this revolutionary screening technology in the Canadian market. With these insights, Labtician was able to find ways to bring this technology to Canadians using existing care models. The CAN Health Network is focused on building an integrated market and supporting Canadian companies scale.

“More retina screening means earlier intervention, better care, and a massive savings to the system,” said Dr. Ike Ahmed, world renowned Ophthalmologist and Medical Director at Prism Eye Institute, who has led the efforts as part of his commitment to the CAN Health Network. “We are strong supporters of the CAN Health Network and helping world-class Canadian health tech companies succeed. By supporting Canadian companies, our patient’s community and economy all benefit.”

About Labtician
With 60 years of history in Canada, Labtician has evolved from a manufacturer of quality ophthalmic products for the global market to a specialized commercialization partner for the Canadian ophthalmic market. In their capacity as a commercialization partner, they offer the “complete Canadian solution.” Labtician is actively involved in the entire commercialization process from pre-launch, to launch and post-launch. This involves regulatory, market access, importation and distribution as well as sales and marketing activities. Internationally, they offer commercialization expertise through global partners.

About DIAGNOS
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based of its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA’s AI-based image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

Additional information is available at www.diagnos.ca and www.sedar.com.

Please send any questions to info@labtician.com

This press release contains forward-looking information. We cannot guarantee that the forward-looking information mentioned will prove to be accurate, as there may be a significant discrepancy between actual results or future events and those mentioned in this statement. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this press release is expressly covered by this caution.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.